Nils Brünner

Biography

Board member since 2017. Nils Brünner Brünner was also CEO of WntResearch between 2012 and 2016, and was in 2016 the Medical Director of WntResearch and was responsible for designing and performing the late preclinical phases and clinical development of WntResearch's leading drug candidate Foxy-5. He has many years of experience from conducting laboratory research into clinical phase. Nils Brünner has published more than 370 scientific articles on cancer research and is a medical doctor in medical oncology, doctor of medical science, professor of pathobiology and biomedicine. He is currently leading a research laboratory at the University of Copenhagen. Nils Brünner also has experience as a consultant for several pharmaceutical and biotech companies and co-founder of Oncology Venture, a biotech company listed on Aktietorget. And lastly, Scandion Oncology A / S, Denmark where Nils is chairman of the board. Born 1952. Other ongoing assignments: Executive Board in TIMPCO ApS (Denmark) and TIMPCO NB ApS (Denmark). Chairman of Scandion Oncology A / S (Denmark).

Research Interest

 conducting laboratory research into clinical phase.